No recorded meetings with EU commissioners.
Mission & Goals
Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission are our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.
EU Legislative Interests
• Directive proposal (COM(2023) 192 final) “Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC” • Regulation proposal (COM(2023) 193 final) “Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL laying down Union procedures for the authorization and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency” • Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) • EU cardiovascular health plan: the Safe Hearts Plan • Digital Fairness Act • Targeted evaluation of Regulation (EU)2017/745 on Medical Devices and Regulation (EU)2017/746 on In vitro Diagnostic Medical Devices • Guidelines on the details of the various categories of variation, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use, and on the documentation to be submitted pursuant to those procedures • The Critical Medicines Act 2025/0102(COD) • Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements • Directive (EU) 2024/3019 of the European Parliament and of the Council of 27 November 2024 concerning urban wastewater treatment (recast) • DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Directive 2000/60/EC establishing a framework for Community action in the field of water policy, Directive 2006/118/EC on the protection of groundwater against pollution and deterioration and Directive 2008/105/EC on environmental quality standards in the field of water policy • One Substance One Assessment (OSOA) Package: Proposal for a Directive of the European Parliament and of the Council amending Directive 2011/65/EU • Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures • Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC • Regulation of the European Parliament and the Council on packaging and packaging waste, amending Regulation (EU) 2019/1020, and repealing Directive 94/62/EC • Proposal for a directive of the European Parliament and of the Council on substantiation and communication of explicit environmental claims (Green Claims Directive) 2023/0085(COD) • Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 laying down harmonised rules on artificial intelligence and amending Regulations (EC) No 300/2008, (EU) No 167/2013, (EU) No 168/2013, (EU) 2018/858, (EU) 2018/1139 and (EU) 2019/2144 and Directives 2014/90/EU, (EU) 2016/797 and (EU) 2020/1828 (Artificial Intelligence Act) • Regulation (EU) 2025/327 of the European Parliament and of the Council on the European Health Data Space • Public Consultation to EU Audiovisual Media Services Directive (AVMSD) 2010/13/EU as amended by Directive 2018/1808
Communication Activities
Opella communications activities in 2025 included participation in events, missions, and publication launches, primarily through its participation as a member of various trade associations. - EU-ASEAN Business Council Annual Brussels Business Mission, March 2025 - A HOLISTIC APPROACH TO PROBIOTICS IN THE EU FOR INFORMED CONSUMERS AND A SUSTAINABLE FOOD INDUSTRY, Jan 2025 (through IPA Europe) - https://www.ipaeurope.org/wp-content/uploads/2024/12/MANIFESTO-IPA-EU-ONLINE.pdf - Exploring Probiotics in the EU: From Policy Dialogue to Socio-Economic Impact and Consumer Awareness, 2 Dec 2025 (through IPA Europe) - https://www.ipaeurope.org/ipa-europe/socio-economic-impact-assessment/ - Organisation of Annual Meetings and of conferences covering topics of interest for AESGP members. Publications on topics relevant for the association. Further details available at: www.aesgp.eu - Organisation of Annual Meetings and of conferences, covering topics of interest for World Federation of Advertisers (WFA) members. Publications on topics relevant for the association. Further details available at: https://wfanet.org/ - Opella partnership with the EIC - European Innovation Council - Corporate Day on 12-13 November 2025 - https://www.linkedin.com/posts/opella-health_eic-corporate-day-with-opella-activity-7402372006278533120-VoC6?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAklkQBbHNqWjeVeyqFmVIOgSFcot3k5DQ
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Membership to Brussels-based Self-Care Trade Associations covering EU: 1. AESGP - Association of the European Self-Medication Industry 2. IPA Europe - International Probiotics Association-Europe 3. FSE - Food Supplements Europe 4. WFA - World Federation of Advertisers Membership to Self-Care Trade Associations in Key EU Countries: 1. NeRES - NOUVELLE ÈRE DE SANTÉ PLUS RESPONSABLE (France) 2. Pharma Deutscheland (Germany) 3. PAGB - Proprietary Association of Great Britain (United Kingdom) 4. Fedechimica Assosalute (Italy) 5. ANEFP - Asociación Española de Autocuidado de la salud (Spain) 6. PASMI - Polish Association of self-medication industry (Poland) 7. RASCI - Romanian Association for medicines without prescription, food supplements and medical devices (Romania) 8. APIFARMA - Portuguese Pharmaceutical Industry Association (Portugal) 9. IGEPHA - Austrian Self Care Association (Austria) 10. BACHI - Belgian Association on Over-the-Counter Medicines (Belgium) 11. EFEX - Greek Self-Care Association (Greece) Key Global Industry Associations: 1. Global Self-Care Federation - https://www.selfcarefederation.org/ 2. Business at OECD - https://www.businessatoecd.org/
Organisation Members
Prior to 30 April 2025, Opella was operating as "Sanofi Consumer Healthcare" as a fully owned global business unit of Sanofi. Hence, the financial reporting of the consumer healthcare business was subsumed under Sanofi, and lobbying activities of the consumer healthcare business unit were all reported under Sanofi's EU Transparency Register number (61291462764-77). On April 30, 2025, Opella became an independent group following the acquisition by Clayton, Dubilier & Rice (CD&R) of a 50.0% controlling stake in Sanofi's consumer healthcare business. Following this transaction, Sanofi retains a 48.2% stake and Bpifrance holds a 1.8% stake in Opella. More details can be found on the following links to the press releases: 1.Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader - https://url.de.m.mimecastprotect.com/s/XzjFCGRLLEHA9MJEtKfjTBGaIO?domain=sanofi.com 2. Press Release. Opella launches as an independent company to redefine the future of self-care. | Opella - https://url.de.m.mimecastprotect.com/s/XzjFCGRLLEHA9MJEtKfjTBGaIO?domain=sanofi.com 3. Sanofi and CD&R close Opella transaction, create global consumer healthcare leader — CD&R | Building Businesses Building Value - https://url.de.m.mimecastprotect.com/s/XzjFCGRLLEHA9MJEtKfjTBGaIO?domain=sanofi.com To know more about our global footprint, see link on our website --> https://www.opella.com/en/meet-opella/our-locations Below are the Opella affiliates in our key European markets where we are members of the national trade associations. 1) Opella Healthcare France SAS 2) A. Nattermann & Cie. GmbH 3) Opella Healthcare UK Limited 4) Opella Healthcare Italy S.R.L. 5) Opella Healthcare Spain S.L.U. 6) Opella Healthcare Poland S.p. z.o.o 7) Opella Healthcare Romania S.R.L. 8) Opella Healthcare Portugal Unipessoal Lda 9) Opella Healthcare Austria GmbH 10) Opella Healthcare Belgium NV/SA 11) Opella Healthcare Greece Single Member Ltd.
Additional Information
Opella was operating as "Sanofi Consumer Healthcare" as a global business unit of Sanofi Group prior to 30 April 2025. Until its separation, Sanofi Group reported on Opella/Consumer Healthcare financials in its Annual Financial Reports, see below: • FY 2023: 2023 FORM 20-F (see page 67 for reporting of Consumer Healthcare total net sales) - https://url.de.m.mimecastprotect.com/s/pAPkCMZRR6tzYZ5DIQtXT80Hof?domain=sanofi.com • FY 2024: 2024 Form 20-F (reporting on Sanofi exclusive negotiations with CD&R) -https://url.de.m.mimecastprotect.com/s/HrW4CNOVVRIjpBNJH0ulTyOEwi?domain=sanofi.com • FY 2025: 2025 form 20-F (see page 17 “It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date, corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier & Rice (CD&R).”) -https://url.de.m.mimecastprotect.com/s/vyX1COgWWRuvkKAlSACKTG1NNB?domain=sanofi.com Opella published its financial report for FY25 covering the period from January 2025 to December 2025, available in this link for transparency - https://url.de.m.mimecastprotect.com/s/U4HqCPj008f3nx49SZFmTxh3XU?domain=investors.opella.com - to view this report, please request access and agreement to an NDA. While Opella was a global business unit of Sanofi, all lobbying activities, trade association engagement and use of intermediaries have been aggregated and reported by Sanofi on the EU Transparency Register. In 2025, Opella has not used any intermediaries or such agencies to represent the company in the EU Institutions or undertaken any such activities subject to Transparency Reporting. Opella has focused solely on its membership in various Trade Associations for its engagement and lobbying activities, identified in Section 12 and reported above as a proportion of annual membership fees.